Core binding factor acute myeloid leukemia
MONDO:0850269An acute myeloid leukemia that is characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.
3085 clinical trials for this condition and its sub-types, 5 tagged with Core binding factor acute myeloid leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New cocktail of 5 drugs targets tough leukemia
Disease control Recruiting nowThis phase 2 trial is testing a combination of five drugs (fludarabine, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin) in 270 people with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome that have specific genetic changes. The goal…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for young AML patients: targeted drug combo tested in phase 2 trial
Disease control Recruiting nowThis study tests two different drug combinations for younger adults with a specific type of acute myeloid leukemia (CBF-AML). One group gets standard chemotherapy plus a targeted antibody, while the other gets the same chemotherapy plus a newer targeted pill. The goal is to see w…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for High-Risk leukemia: stem cell transplant trial launches
Disease control Recruiting nowThis study tests whether a stem cell transplant from a donor can help people with a high-risk type of acute myeloid leukemia (AML) stay cancer-free longer. Participants receive the transplant after initial chemotherapy. The trial tracks survival, relapse, and side effects in 90 n…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC